A comparison of tumor growth showed that CDH17 x GUCY2C BsADC treatment resulted in significant tumor regression compared to CDH17-ADC or GUCY2C-ADC treatment (Fig. 5A). The gene discussed is CDH17; the disease is neoplasm.